CENTESSA PHARMACEUTICALS-ADR (CNTA)
US1523091007 - ADR
Get insights into the top gainers and losers of Thursday's pre-market session.
Get insights into the top gainers and losers of Thursday's pre-market session.
Top movers in Tuesday's pre-market session
Pre-market stock analysis on 2024-11-19: top gainers and losers in today's session.
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update
Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived...
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
Late-breaking poster presentation of non-human primate (NHP) data support ORX142 as novel drug candidate for the treatment of excessive daytime sleepiness...
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
The company tested a potential narcolepsy treatment in healthy, but sleep-deprived, volunteers.
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT)Favorable safety...
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness (EDS)
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
ORX142 is currently in IND enabling activities for select neurological, neurodegenerative, and psychiatric disorders with excessive daytime sleepiness...
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
BOSTON and LONDON, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
CNTA Stock Earnings: Centessa Pharmaceuticals Misses EPS for Q2 2024
CNTA stock results show that Centessa Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
CNTA Stock Earnings: Centessa Pharmaceuticals Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Centessa Pharmaceuticals (NASDAQ:CNTA) just reported results for the second qua...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024
Company advancing pipeline of potential best-in-class orexin receptor 2 (OX2R) agonists Initiated Phase 1 clinical study with ORX750 being developed for...
Investors Pick Up CNTA Even Cheaper Than Its Secondary Stock Offering
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
BOSTON and LONDON, June 10, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims...
Notable Two Hundred Day Moving Average Cross - CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to...
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024
CNTA stock results show that Centessa Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Centessa Pharmaceuticals (NASDAQ:CNTA) just reported results for the first quar...
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis...
Investors Pick Up CNTA 6.2% Cheaper Than Its Secondary Stock Offering
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that...
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that...